Switch to:

Strongbridge Biopharma Piotroski F-Score

: 3 (As of Today)
View and export this data going back to 2015. Start your Free Trial

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Strongbridge Biopharma has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

NAS:SBBP' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Max: 5
Current: 3

2
5

During the past 6 years, the highest Piotroski F-Score of Strongbridge Biopharma was 5. The lowest was 2. And the median was 4.


Strongbridge Biopharma Piotroski F-Score Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Strongbridge Biopharma Annual Data
Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Piotroski F-Score Premium Member Only 0.00 3.00 2.00 4.00 5.00

Strongbridge Biopharma Quarterly Data
Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 5.00 4.00 3.00

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Strongbridge Biopharma Piotroski F-Score Distribution

* The bar in red indicates where Strongbridge Biopharma's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

This Year (Jun19) TTM:Last Year (Jun18) TTM:
Net Income was -20.558 + 84.056 + -18.434 + -8.247 = $36.82 Mil.
Cash Flow from Operations was -19.316 + -32.712 + -18.308 + -18.103 = $-88.44 Mil.
Revenue was 5.347 + 4.514 + 4.343 + 6.079 = $20.28 Mil.
Gross Profit was 3.906 + 3.389 + 3.53 + 5.057 = $15.88 Mil.
Average Total Assets from the begining of this year (Jun18)
to the end of this year (Jun19) was
(156.212 + 140.849 + 170.285 + 153.482 + 135.156) / 5 = $151.1968 Mil.
Total Assets at the begining of this year (Jun18) was $156.21 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $98.18 Mil.
Total Current Liabilities was $18.50 Mil.
Net Income was -35.06 + -18.748 + -28.723 + -2.923 = $-85.45 Mil.

Revenue was 2.533 + 2.984 + 3.87 + 4.296 = $13.68 Mil.
Gross Profit was 1.942 + 2.469 + 3.203 + 3.543 = $11.16 Mil.
Average Net Income from the begining of last year (Jun17)
to the end of last year (Jun18) was
(103.712 + 92.105 + 103.925 + 163.527 + 156.212) / 5 = $123.8962 Mil.
Total Assets at the begining of last year (Jun17) was $103.71 Mil.
Long-Term Debt & Capital Lease Obligation was $77.57 Mil.
Total Current Assets was $92.15 Mil.
Total Current Liabilities was $14.27 Mil.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Strongbridge Biopharma's current Net Income (TTM) was 36.82. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Strongbridge Biopharma's current Cash Flow from Operations (TTM) was -88.44. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets(Jun18)
=36.817/156.212
=0.23568612

ROA (Last Year)=Net Income/Total Assets(Jun17)
=-85.454/103.712
=-0.8239548

Strongbridge Biopharma's return on assets of this year was 0.23568612. Strongbridge Biopharma's return on assets of last year was -0.8239548. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Strongbridge Biopharma's current Net Income (TTM) was 36.82. Strongbridge Biopharma's current Cash Flow from Operations (TTM) was -88.44. ==> -88.44 <= 36.82 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (Last Year: Jun18)=Long-Term Debt & Capital Lease Obligation/Total Assetsfrom Jun17 to Jun18
=77.572/123.8962
=0.62610476

Strongbridge Biopharma's gearing of this year was 0. Strongbridge Biopharma's gearing of last year was 0.62610476. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun19)=Total Current Assets/Total Current Liabilities
=98.182/18.504
=5.30598789

Current Ratio (Last Year: Jun18)=Total Current Assets/Total Current Liabilities
=92.154/14.267
=6.45924161

Strongbridge Biopharma's current ratio of this year was 5.30598789. Strongbridge Biopharma's current ratio of last year was 6.45924161. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Strongbridge Biopharma's number of shares in issue this year was 55.8. Strongbridge Biopharma's number of shares in issue last year was 50.4. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=15.882/20.283
=0.78302026

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=11.157/13.683
=0.81539136

Strongbridge Biopharma's gross margin of this year was 0.78302026. Strongbridge Biopharma's gross margin of last year was 0.81539136. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun18)
=20.283/156.212
=0.12984278

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun17)
=13.683/103.712
=0.13193266

Strongbridge Biopharma's asset turnover of this year was 0.12984278. Strongbridge Biopharma's asset turnover of last year was 0.13193266. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Strongbridge Biopharma has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Strongbridge Biopharma  (NAS:SBBP) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Strongbridge Biopharma Piotroski F-Score Related Terms


Strongbridge Biopharma Piotroski F-Score Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}